Phase 1a data in 16 patients with recurrent glioblastoma established a recommended dose for expansion of LP-184 for a planned phase 1b/2a combination trial.
|Poll|May 28, 2014
67-Year-Old Man Presents With Abdominal Pain & Bloody Stools
Author(s)Cesar A. Moran, MD
A 67-year-old man presents with abdominal pain and bloody stools. Diagnostic imaging reveals the presence of a mass in the right colon and a solitary mass in the liver. Sections of the colon mass and liver are shown. What is your diagnosis?
Advertisement
A 67-year-old man presents with abdominal pain and bloody stools. Diagnostic imaging reveals the presence of a mass in the right colon and a solitary mass in the liver. Sections of the colon mass and liver are shown below, respectively.
What is your diagnosis?
Advertisement
Related to this article
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
The FDA approved pimicotinib for TGCT based on phase 3 MANEUVER data showing durable responses and improved pain, stiffness, and function.
Real-world data showed a 68% 12-month high-grade recurrence-free survival rate with hyperthermic mitomycin C in patients with BCG-unresponsive NMIBC.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Evolving Perioperative Treatment Landscape for Resectable Gastric and Gastroesophageal Junction Cancers: A Q&A with Dr Nataliya Uboha
5